INPPL1 and cervical cancer: Azzi investigated the effects of SH2‐domain containing phosphatidylinositol‐3,4,5‐trisphosphate 5‐phosphatase (SHIP2) inhibition by AS1938909 on H2O2‐induced phosphoinositide 3‐kinase/protein kinase B and mitogen‐activated protein/extracellular signal‐regulated kinase pathways in two cervical cancer cell lines, HeLa and SiHa.